A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subject

Trial Profile

A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subject

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Paricalcitol (Primary)
  • Indications Renal failure
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 03 Apr 2018 Status changed from recruiting to completed.
    • 03 Apr 2018 New trial record
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top